Please login to Zacks.com or register to post a comment.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| SCIENTIFIC L | SCIL | 8.00% |
| NATUS MEDICA | BABY | 6.11% |
| SUMMER INFAN | SUMR | 6.02% |
| RADIANT LOGI | RLGT | 5.32% |
| NEW ORIENTAL | EDU | 4.51% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
Atmel Corporation ( ATML - Analyst Report ) recently slashed its revenue guidance for the fourth quarter of 2011. The company expects revenues of $384 million, down 20% sequentially. The updated guidance is a significant decline from the previous provided range of 12% – 16% down sequentially which implied a revenue guidance of $403 million and $422 million.
The top-line was negatively affected by approximately $11 million as a result of rescheduling payments on a receivable related to an Asian distributor.
Nevertheless, Atmel continues to expect gross margin of 48.0%, +/- 0.5%. Earnings estimates for 2011 have been static of late but declined a bit for 2012.
Earlier, Atmel Corporation reported revenues of $479.4 million in the third quarter of 2011, up 8% year over year and almost flat sequentially.Excluding the impact of the divestiture of the Smart Card business, revenues grew 15% year over year.
Net income came in at $116.7 million or $0.25 per diluted share compared with a net income of $90.9 million or $0.19 per diluted share in the second quarter of 2011 and a net income of $219.8 million or $0.47 per share in the year-ago quarter. Excluding one-time items but including stock-based compensation expense, net income came in at $0.23 per share, beating the Zacks Consensus Estimate of $0.20.
Although earnings beat the Zacks Consensus Estimate in the third quarter, Atmel saw a significant decline in the industrial segment and a one-time inventory adjustment in non-Apple ( AAPL - Analyst Report ) tablets.
Atmel has a growing microcontrollers business that should contribute to the company's top-line growth going forward. We believe the tablet inventory correction should be done with the next quarter and demand should return to normal levels.
As of now, we maintain our Neutral recommendation ahead of the company’s fourth quarter results on February 8, 2012. The stock price plummeted 5% with the news of the cut in guidance but recovered quite a bit thereafter. Our recommendation is supported by Zacks #3 Rank which translates into a short-term rating of Hold.
Read the full reports :
Analyst Report on ATML
Analyst Report on AAPL